LEAGUE-1 study findings on a dual oral hepatitis C virus therapy consisting of daclatasvir and simeprevir, without interferon or ribavirin, are encouraging.
Rates of sustained virologic response ranged from 70% to 90% among patients with HCV and HIV coinfection in the PHOTON-1 study.
Direct-acting investigational "three-D" combination therapy achieves more than 99% sustained virologic response in patients hepatitis C genotype 1b.
Simeprevir plus pegylated interferon and ribavirin promising in previously untreated patients with hepatitis C and HIV coinfection.
A six-week combination regimen appeared to be as effective as 12 weeks of therapy for patients with hepatitis C virus infections.